These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, report not yet due 2007-005241-38 A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) wit... 2008-09-24 not-yet-due
Not reported 2009-012705-19 A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid A... 2010-09-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-016973-13 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome 2014-02-12 bad-data
Not reported 2011-003532-32 Phase 2 Assessment of the Relationship between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Preliminar... 2013-09-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003460-47 A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not ... 2016-03-17 bad-data
Reported results 2013-001543-31 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome 2016-04-20 due-trials
Listed as ongoing, but also has a completion date 2013-002596-18 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) 2018-09-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-005153-39 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1... 2017-06-23 bad-data
Reported results 2015-001709-15 A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes 2017-05-18 due-trials